Total Funding

$2 M

Prosetta Summary

Company Summary

Prosetta Biosciences, Inc. is a 12-year old biotechnology company developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS) by scientists at the University of California, San Francisco and the University of Washington, Seattle. The incorporation of the CFPSS in our drug discovery platform, has lead to the identification of small molecules which disrupt or alter the key protein-protein interactions involved with the assembly of viral capsids (the protein shell that protects the DNA or RNA genome of a virus). Prosetta has successfully produced highly potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against Influenza, HIV and HCV.
San Francisco, CA, US | view all locations
Cybersecurity rating

Key People

  • Thomas Higgins

    Thomas Higgins, Chairman of the Board of Directors

    • Vishwanath R. Lingappa

      Vishwanath R. Lingappa, Chief Executive Officer, Chief Technology Officer, and Member of the Board of Directors

      • Karl Manheim

        Karl Manheim, Member of the Board of Directors

        • Dale Bredesen

          Dale Bredesen, Member of the Board of Directors

          LocationsView all

          1 location detected

          • San Francisco, CA HQ

            United States

            670 5th St, San Francisco

          Footer menu